
Consortium sells Carmel Pharma stake
A consortium, consisting of Priveq Investment, Investor Growth Capital, Industrifonden, Start Invest and employees, has sold 95% of the shareholding in Swedish pharmaceutical company Carmel Pharma AB.
The acquirer is Becton, Dickinson and Company, which also intends to acquire the remaining shares for the same offer price. Financial details of the deal have not been disclosed.
Previous funding
3i acquired a 23% stake in Carmel Pharma from Scandinavian Life Science Venture in October 2006. Priveq Investment acquired the stake held by 3i in May 2009.
Company
Carmel Pharma AB is based in Mölndal and is a provider of closed drug transfer systems for handling medication. The company's product PhaSeal is used in more than 2,000 hospitals worldwide.
The company was founded in 1994 and employs approximately 200 staff.
People
Loise Nilsson represented Priveq on Carmel Pharma's board of directors.
Advisers
Vendor - Jefferies International (Corporate finance); Gernandt & Danielsson (Legal).
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater